Jacobs, BrandonPalmer, NicholasShetty, TruptiDimaras, HelenHajrasouliha, AmirJusufbegovic, DenisCorson, Timothy W.2022-03-022022-03-022021Jacobs, B., Palmer, N., Shetty, T., Dimaras, H., Hajrasouliha, A., Jusufbegovic, D., & Corson, T. W. (2021). Patient preferences in retinal drug delivery. Scientific Reports, 11(1), 1-10. https://doi.org/10.1038/s41598-021-98568-7https://hdl.handle.net/1805/28024Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs, with relatively low patient compliance and potential risks. Ongoing research explores alternative RVD treatments, including eye drops and oral tablets. This study surveyed RVD patients treated with IVT injections to establish factors influencing low compliance rates while gauging treatment delivery method preferences. Demographics, perspectives, and treatment preferences were collected via IRB-approved, self-administered survey sent to Glick Eye Institute patients treated via IVT injections. Demographics, diagnoses, and treatments were ascertained from respondents’ medical records. Gender, age, and number of IVT injections received were used as stratifications. Five-level Likert-style scales and t-tests evaluated responses and stratification comparisons. The most common diagnoses in the respondent population (n = 54; response rate = 5%) were age-related macular degeneration, macular edema, and diabetic retinopathy. Respondents had varying levels of education, income, and age. Most (83%) admitted feeling anxious prior to their first IVT injection, but 80% reported willingness to receive IVT injections indefinitely, with a preference for ophthalmologist visits every 1–3 months. Eye drops would be preferred over IVT injections by 76% of respondents, while 65% preferred oral tablets, due to several perceived negative factors of IVT injections and positive factors for eye drops. Stratified groups did not differ in responses to survey questions. RVD patients will accept IVT injections for vision preservation, but alternative delivery methods like eye drops or oral tablets would be preferred. Thus, development of eye drop and oral therapeutics for RVD treatment is further emphasized by these findings.enAttribution 4.0 Internationalretinal vascular diseasesdrug deliverypatient preferencesArticle